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A B S T R A C T
Recent research strongly supports the hypothesis that posttraumatic stress disorder (PTSD) can be accompanied
by obesity and related metabolic disturbances. The mechanisms of these associations are however still not well
defined, although disturbed functions in the sympathetic-adrenergic nervous system together with the disturbed
release of hormones via the endocrine HPA (hypothalamic-pituitary-adrenal) axis apparently play a role. Leptin
resistance and ghrelin excesses might contribute to a disturbed hypothalamic function, and also disturb other
cerebral functions, leading to dysfunctional reward signaling and uncontrolled appetite combined with a ten-
dency to alcohol abuse. Secondarily, cortisol stimulation will contribute to the development of central obesity
which is known to facilitate the development of metabolic syndrome, including slightly increased levels of
inflammatory biomarkers such as C-reactive protein and fibrinogen. While previous therapeutic strategies have
focused on early psychotherapeutic interventions in PTSD, the present review emphasizes the importance of
better therapeutic approaches regarding the somatic correlates of the syndrome. Strict regulation of dietary
meals and food composition with minimal intake of sweets and saturated fat, as well as alcohol avoidance, can
provide a basic therapeutic framework. A cognitive psychotherapeutic approach with graduated desensitization
toward trigging factors, combined with pharmacotherapy, is discussed in the present review.
1. Introduction
Today, obesity and its comorbidities represent a significant global
health challenge, and the number of people with obesity is still in-
creasing [1,2]. In Scandinavia and in the United States, the prevalences
of obesity in the general populations are now about or above 25% and
35%, respectively [3,4]. And worldwide the obesity rates present an
increasing trend [5]. Obesity has been attributed to a sedentary lifestyle
together with affluent intake of energy-rich food with copious amounts
of fat and sugar [6]. However, in recent years psychological factors
including anxiety, emptiness feelings, and posttraumatic stress have
emerged as possible background factors of obesity and its comorbidities
[7,8]. Here, it is relevant that the prevalence rate of the severe variant
of stress, posttraumatic stress disorder (PTSD), is also rather high, with
variations around 8% in populations in the Western world [9–13].
PTSD is characterized by symptoms of relapse of the traumatic event
(flashbacks), and symptoms of increased irritability together with
concentration difficulties, and increased alertness to stimuli that re-
minds of the traumatic event [14]. Symptoms may occur early or a few
weeks after the trauma, but in some cases, the latency time is con-
siderably longer [15]. Anxiety, depression, suicidal thoughts, alcohol or
drug abuse, can follow PTSD [16]. Also in uncomplicated cases, PTSD
represents a significant burden on our society.
Of particular relevance is that PTSD in recent studies appears to be
linked to obesity development and metabolic complications. The large
health costs associated with complicated PTSD accompanied by co-
morbidities will give rise to a significant burden on health care systems
and affected individuals [17]. A range of obesity-related diseases may
accompany PTSD, such as type 2 diabetes (T2DM), insulin resistance,
cardiovascular disease, and dyslipidemia [18,19]. But still, there is no
current strategy for treating or preventing PTSD associated metabolic
disturbances, and further research has been requested [20,21].
The present review aims at updating our knowledge on relations
between obesity and PTSD, as well as clarifying the challenges related
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to the treatment of PTSD-associated metabolic dysfunctions with the
purpose of improving therapeutic strategies.
2. Stress, anxiety, PTSD, and somatic manifestations
Somatic manifestations of PTSD appear to occur through neuro-
endocrine links leading to activation of the sympathetic-adrenergic
nervous system together with the release of hormones via the endocrine
HPA (hypothalamic-pituitary-adrenal) axis [22]. Even anxiety and non-
specific stress can affect neuroendocrine links and the HPA axis (Fig. 1),
thereby leading to increased levels of circulating cortisol, and secon-
darily also the development of metabolic dysfunctions and central
obesity [23,24]. PTSD has been linked to a significantly (about 1.5-fold)
elevated risk to develop obesity [25]. Also, childhood adversity is
considered to predispose individuals to the development of complex
PTSD and secondarily to central obesity later in life [26]. Furthermore,
childhood traumatic events have been linked with metabolic syndrome,
and also the development of T2DM and cardiovascular disease [18].
High levels of stress-related hormones, especially catecholamines and
cortisol, seem to predispose for altered adipokine profile accompanied
by metabolic complications, in particular, if traumatic events occurred
in early life, either childhood or adolescence [27,28]. Although the
catecholamines and some other factors [29] may induce lipolysis
(Fig. 1), this effect appears to be counteracted by hyperinsulinemia and
the leptin resistance characterizing obesity [30–32].
Clinical practice suggests that stress often accompanies arterial
hypertension. A meta-analysis of a large-scale population-based study
performed in practically healthy young people showed that psycholo-
gical factors like anxiety, anger, chronic stress, and post-traumatic
stress disorder are connected with an elevated occurrence of cardio-
vascular pathology approximately 1.5 times, which indicates the causal
role of psychological factors in these diseases [33].
Different hypotheses explain the connection between psychological
stress and cardiovascular disease development. One of these hypotheses
is that epigenetic programming of the hyperactive stress response
system in a fetus of a mother under stress can lead to autonomic,
neuroendocrine, and immune dysfunction. This subsequently leads to
an atherosclerotic process and a negative effect on brain structures by
transmitting negative signals through interoceptive pathways many
years before the development of arterial hypertension or other cardio-
vascular diseases [34]. Moreover, adaptive changes in the cardiovas-
cular system in response to external stressful situations can lead to
cardiometabolic and structural changes in arteries, endothelial dys-
function, and development of hypertension. In turn, cardiovascular
events can provoke psychological acute-phase reactions, which may
lead to the development of depression, anxiety, and post-traumatic
stress disorder [35].
Psychological factors and stress are usually associated with beha-
vioral and lifestyle problems such as smoking, physical inactivity, poor
nutrition, alcohol abuse, and sleep problems. Stress-related health be-
haviors contribute to the development of traditional cardiometabolic
risk factors, including hypertension, dyslipidemia, insulin sensitivity,
and increase in body mass index [36].
Inflammation characterized by increased levels of biomarkers such
as CRP, tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6),
also appear to occur more frequently in adults who have been exposed
to adversity early in life [37]. Individuals with obesity and metabolic
comorbidities, including T2DM and cardiovascular disease, have also
often experienced other psychological stressors, such as social isolation
or socioeconomic difficulties [38]. It is conceivable that constant stress
related to lack of social contacts and emptiness feelings can lead to
increased intake of fast-food with a high content of sugar and saturated
fat [39].
3. Potential mechanisms in the links between chronic stress,
PTSD, and obesity
By using a rat model of PTSD, Edwards et al. [40] found that the
animals could use alcohol consumption in their strategies to deal with
traumatic stress, and these investigators also reported altered cerebral
activities in prefrontal and temporal loci of the animals. Secondarily,
disturbances in neuro-endocrine links appear to lead to increased or
uncontrolled consumption of high-fat foods, sugar and even alcohol in
the animals [41]. It is known from observations in humans that severe
PTSD symptoms to a significant degree are comorbid with alcohol
misuse and dependence [42]. Increased PTSD symptoms are also linked
to more frequent alcohol cravings, presumably through activation of
reward systems in the amygdala or locus coeruleus [43]. Consumption
of alcohol may also aggravate the impacts of stress-induced neu-
ropsychiatric outcomes. For example, the volume of the hippocampus
has been found to be reduced in patients with PTSD [44], and it is well
known that alcohol abuse may exacerbate these deficits [45]. Ideally,
alcohol or drug abuse should, therefore, be carefully monitored in fu-
ture studies on PTSD.
PTSD also leads to disturbed functions of satiety hormones. During
the vicious circle of affluent intake of high-fat food combined with
sweets and alcohol abuse, comorbidities with hyperinsulinemia and
leptin resistance, as well as ghrelin disturbances may develop. And
severe PTSD symptoms have been linked to obsessive disorder with
emotional eating [46].
Observed changes in cognition reported in patients with PTSD may
be related to changes that lead to amplification of reward activation of
consumptive behaviors. Earlier PTSD studies have reported various
degrees of structural changes in amygdala and hippocampus, which
may reflect the severity of PTSD symptoms [47]. These changes may
also influence brain responses to food intake stimulants, and thereby
contribute to the development of obesity [25].
Fig. 1. Effects of PTSD via the sympathetic nervous system and via the hy-
pothalamus-pituitary-adrenal axis (HPA axis). While the adrenaline and nora-
drenaline response gives rise to increased blood pressure, increased cortisol
levels are associated with central obesity.
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4. Obesity, metabolic disorders, and leptin resistance
In addition to a dysfunctional endocrine HPA axis, patients with
PTSD appear to have alterations of the cerebral reward systems, ac-
companied by enhanced dopamine release in nucleus accumbens,
which is known to be a key aspect both of disturbed eating behaviors
and drug, alcohol or gambling addiction [48]. Some studies of func-
tional changes in the brain of PTSD patients have reported that these
changes overlap with appetite-related brain areas. For example, a
functional MRI study showed that PTSD patients tested during the
performance of a cognitive task with an affective challenge had parietal
and frontal activations [49]. These same areas are presumed to be
implicated in the cognitive control of food intake.
Polypeptide leptin secreted by adipocytes plays a significant role in
the regulation of lipid metabolism. In individuals with severe obesity,
elevated leptin levels and leptin resistance are usually observed. Leptin
can inhibit the transcription of the insulin gene and its secretion
through the sympathetic nervous system [50]. Recent studies have
shown that leptin contributes to the development of oxidative stress
through enhancing the macrophages phagocytic activity and the in-
duction of pro-inflammatory cytokine synthesis (TNF-a, IL-6, IL-2) and
interferon-gamma. It leads to damage of endothelial cells, monocytes,
neutrophils, and also increased levels of markers for endothelial cell
dysfunction [51]. It has been suggested that the pro-inflammatory ef-
fects of leptin are associated with structural and functional similarity
with the IL-6 cytokine [52]. Obesity can be characterized as chronic
low-grade inflammation with an ever-increasing level of oxidative
stress. After exceeding a certain level, oxidative stress damages cellular
structures which lead to a decrease in the synthesis of antioxidant
substances and the development of complications associated with
obesity [53]. In a study conducted on rats with genetically determined
obesity, it was shown that hyperphagia entailed hyperinsulinemia fol-
lowed by increased lipogenesis. This leads to ectopic deposition of
triacylglycerol outside adipocytes, increased formation of fatty acids,
impaired non-oxidative metabolism, and ceramide synthesis, which
causes functional changes and apoptosis in beta cells and cardiomyo-
cytes with subsequent development of cardiomyopathy [54]. Increased
size and number of adipocytes leads to hyperproduction of cytokines,
decreases the sensitivity of the peripheral tissues to insulin, accelerates
atherogenic processes, and increase the levels of free fatty acids, tri-
glycerides, and low-density lipoproteins, hyperlipidemia, hypergly-
cemia, and hypertension.
It has been suggested that both hyperinsulinemia and leptin dys-
function are consequences of PTSD. Failure of increased leptin levels to
suppress appetite and mediate weight loss characterizes a state of leptin
resistance, which may be observed in morbidly obese individuals [55].
Today it is known that several mechanisms attenuate leptin signaling
and promote hypothalamic leptin resistance. For instance, observations
have indicated that hyperinsulinemia leads to leptin resistance [56,57].
Leptin and insulin appears to share a pathway in the central signaling.
Research indicates that insulin has a role as an endogenous antagonist
to leptin. Thus, normalization of hyperinsulinemia may ameliorate
leptin resistance [58], and may thereby normalize the neuropeptide Y
(NPY) response and secondarily also regulate the HPA-axis.
NPY levels seem to be consistently elevated in individuals who in
their past have had PTSD, but not in currently suffering individuals.
This suggests that NPY may have a function in stress recovery, which
might regulate appetite and eating behaviors [59]. Other adipokines
and appetite-regulating hormones, like adiponectin and ghrelin, need
more research to fully understand their possible relationships with
PTSD.
When using a rodent PTSD model Meyer et al. found that ghrelin,
the hunger hormone, was upregulated by stress [59]. And increases in
ghrelin appeared to be necessary for the implemented stress to increase
the memory of fear since blocking the ghrelin receptor abolished the
stress-related enhancement of fear memory [60]. However, human
studies are indispensable to translate these observations into the ther-
apeutic administration of anti-ghrelin drugs to prevent stress-induced
psychiatric disorders like PTSD and accompanying feelings of hunger
after energy-rich food and sweets.
5. Cytokines
Potential modulators in the interplay between PTSD and obesity, in
addition to leptin and NPY, may be certain cytokines and other adi-
pokines [61] PTSD seems to impact inflammatory biomarkers, in-
directly or directly [62]. Among observed alterations are increased IL-6
[63], and an increase in CRP and the intercellular adhesion molecule 1
(ICAM-1) [64]. A twofold increase in the CRP-value in PTSD has been
observed [65], which is comparable to the CRP increases characterizing
patients with metabolic syndrome [66]. The relationship between
PTSD-associated obesity and T2DM may be mediated through the
concomitantly increased levels of leptin and caveolin 1 [67] And the
accompanying increased serum amyloid A levels together with a per-
sistent elevation of leptin may reflect or contribute to a low-grade in-
flammation with raised cardiovascular risk [68,69]. Another in-
flammatory biomarker, namely fibrinogen, which also operates as a
coagulation factor and thereby is considered a risk biomarker for car-
diovascular disease, is also elevated in PTSD [70]. Thus, in a study
examining, if present stress influences fibrinogen in patients or controls,
the PTSD patients had higher concentrations of fibrinogen both at
baseline and after stress in comparison with controls (persons without
PTSD) [71]. Taken together, research indicates an association between
PTSD and the development of inflammatory and metabolic conditions,
although detailed mechanisms need to be outlined.
6. Discussion
It appears from the reviewed research that patients who have PTSD
also are at increased risk for developing obesity, thereby linking PSTD
to obesity comorbidities such as T2DM, cardiovascular disorders, and
metabolic syndrome. Recent research has substantiated that PTSD in-
creases the risk of metabolic and cardiovascular disorders. PTSD ap-
pears to be the psychiatric disease that most commonly is associated
with obesity [72]. And when PTSD occurs together with depressive
symptoms, it leads to especially high risk to develop metabolic syn-
drome [73], with cardiovascular disease being a frequently occurring
endpoint. Thus, in a prospective study of survivors of the World Trade
Center, persons with PTSD who had been physically injured during the
attacks were found to have had three times increased the risk to develop
cardiovascular disease in comparison with persons without PTSD or
injuries [74]. In another prospective study of survivors of the World
Trade Center attacks, PTSD was found to significantly predict T2DM-
development [75]. Taken together, the studies reviewed in the present
paper show obesity-related and metabolic comorbidities with PTSD.
The suggested mechanisms include altered endocrine responses in the
HPA axis together with functional alterations in the CNS and distortion
of the adipokine interplay.
In this connection, a crucial aim is to address the challenges of
implementing prophylaxis against the development of PTSD-associated
obesity and metabolic dysfunctions. While previous therapeutic stra-
tegies have focused solely on psychotherapeutic interventions [76], it is
clear that somatic PTSD correlates should not be neglected.
An appropriate psychotherapeutic approach in complicated PTSD
appears to be a cognitive behavioral therapy combined with desensi-
tization techniques [77]. Cognitive restructuring and psychoeducation
under optimized therapeutic relationship, combined with exposure via
narrative traumatic experiences as active ingredients may maximize
treatment effects [78]. In addition, therapists should detect alcohol and
drug misuse at an early stage, and dieticians should be part of the
treatment team.
Regarding dietary approach, a rational approach is to recommend a
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basic framework consisting of regular meals together with minimal
intake of sweets and saturated fat. Adequacy with regard to minerals
and trace nutrient appears to be of importance. It has been reported
that magnesium deficiency can exacerbate anxiety and aggravate T2DM
[79]. This may also occur for zinc deficiency [80]. Recent reports have
outlined that a lack of vitamin D is associated with increased anxiety
and pain [81]. When deficient, vitamin D supplementation may have a
positive effect, as adequate vitamin D supplementation can have ther-
apeutic importance in the treatment of anxiety [82]. Long-term dietary
habits with low intake of sugar and adequate intake of mono-un-
saturated and poly-unsaturated fat - from vegetables and fish - is re-
commended for the general population [83]. This is also because of the
importance of adequate intake of fat-soluble vitamins. Several of these
constituents may exert anti-inflammatory effects in metabolic syn-
drome [84].
As regards pharmacological approach, clinical use of anti-ghrelin
treatments may become a successful approach in the future [59], but
human studies are indispensable to translate the positive observations
in animal experiments into therapeutic use for prevention of PTSD and
metabolic complications. Other pharmaceuticals under investigation
are a combination of bupropion and naltrexone, which appear pro-
mising [85]. Recently developments of GLP agonists with once-a-week
administration bear promises with regard to improved prophylaxis of
the pre-diabetic patients [86].
7. Conclusion
In summary, recent research strongly supports the hypothesis that
PTSD leads to obesity and related metabolic disturbances. The me-
chanisms of these associations are however still not well defined.
Further research should try to determine how the significant association
between PTSD and metabolic risks may occur. The present evidence
might suggest that PSTD is linked to altered brain and neuroendocrine
activity leading to altered food consumption and altered food decisions
that cause obesity. But this is not yet fully confirmed. It is also im-
portant in future research to explore the association between PSTD and
altered inflammatory cytokines and adipokines. Of importance, as PTSD
has a prevalence that remains high, this particular type of obesity needs
specific and adequate treatments. Currently, there are not available any
targeted and effective measures for obesity that is associated with
PTSD. Therefore, it is a need to develop and test from bench-to-bed
promising treatment strategies, which target this obesity type.
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